On April 15, 2026 Zephyr AI, Inc. ("Zephyr AI"), a leader in precision medicine harnessing artificial intelligence to accelerate drug development, reported its schedule of research presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting in San Diego, California, April 17-22, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company’s posters will be presented by senior researchers and highlight novel work Zephyr AI is advancing with its biopharmaceutical and life science partners. The presentations feature multimodal AI approaches for predicting response to targeted therapies in patients with cancer, as well as checkpoint inhibitor response in patients receiving combination treatment. Across these investigations, Zephyr’s AI models operate on clinically available inputs—including liquid biopsy DNA, tissue-based molecular data, and whole-slide images—to generate drug response predictions and biological insights into tumor-intrinsic and tumor microenvironment features associated with treatment response.
"We are thrilled to showcase Zephyr AI’s work at this year’s AACR (Free AACR Whitepaper) meeting," said Zephyr AI CEO Allen Chao, PhD. "The utilization of AI with multimodal data and clinically available inputs is transforming research and accelerating discovery. This is a wonderful opportunity to share how our novel approach is helping drive important advances in cancer treatment."
Official schedule of Zephyr AI presentations at AACR (Free AACR Whitepaper):
Real world prediction and biological characterization of sotorasib sensitivity using multimodal AI and liquid biopsy genomic inputs (Presentation 5235)
Session Title: Biomarkers Predictive of Therapeutic Benefit 5
Presenter: Emily Vucic, VP Science
Session Date & Time: April 21, 9:00AM – 12:00PM
Location: Poster Section 42
Poster Board Number: 1
Multimodal AI predicts immune checkpoint inhibitor response from clinically available inputs and whole-slide images with explainable tumor biology and combination therapy insights (Presentation 1014)
Session Title: Biomarkers Predictive of Therapeutic Benefit 1
Presenter: Maayan Baron, Assoc Dir of Computational Biology
Session Date & Time: April 19, 2026 2:00PM – 5:00PM
Location: Poster Section 40
Poster Board Number: 8
Leadership from Zephyr AI will be attending AACR (Free AACR Whitepaper). Please contact [email protected] to request a meeting.
(Press release, Zephyr AI, APR 15, 2026, View Source [SID1234664419])